Results 41 to 50 of about 19,412 (203)

Osimertinib plus Ramucirumab: The Best of Both Worlds? [PDF]

, 2021
Both osimertinib and the combination of erlotinib plus ramucirumab are approved for initial therapy of advanced EGFR mutation-positive non-small cell lung cancer. Osimertinib is also approved in previously treated T790M mutation-positive patients.
Garon, Edward B
core   +1 more source

Inhibition of BRD4 sensitizes NSCLC cells to osimertinib by suppressing APT1 and promoting MST1 palmitoylation

Cell Death Discovery
Osimertinib is widely used to treat non-small-cell lung cancer (NSCLC) carrying epidermal growth factor receptor (EGFR) mutations. However, osimertinib resistance inevitably develops in almost all patients.
Shaoqiang Wang, Yingying Zheng, Zhenyu Zhang, Lijie Qiu, Wolong Zhou, Heng Zhang   +5 more
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Myositis – A common but underreported adverse effect of osimertinib: Case series and review of the literature

Cancer Treatment and Research Communications, 2020
Background: Lung cancer is the second most common cancer in both men and women and the leading cause of cancer death worldwide. The development of novel tyrosine kinase inhibitors (TKIs) represented a paradigm shift in the management of lung cancer and ...
Pawel Parafianowicz, Rohee Krishan, Bryce D. Beutler, Raheel X. Islam, Tejvir Singh   +4 more
doaj   +1 more source

DLST Succinylation‐Mediated Mitochondrial Metabolic Remodeling and Cuproptosis Resistance Promote Malignant Progression of Lung Adenocarcinoma

Advanced Science, EarlyView.
The DLST K409 succinylation mediated by CPT1A promotes OXPHOS and redox homeostasis through regulating enzyme activity, thereby promoting the malignant progression of LUAD. Notably, the succinylation of DLST can enhance the cuproptosis resistance by inhibiting its lipoylation.
Xuanxuan Li, Peijun Zhou, Xingzhi Peng, Qixin Liu, Wenhui Zeng, Rui Wang, Liangfang Shen, Jinwu Peng, Qin Zhou, Lifang Yang   +9 more
wiley   +1 more source

Improving the tolerability of osimertinib by identifying its toxic limit [PDF]

, 2022
BACKGROUND: Osimertinib is the cornerstone in the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer (NSCLC). Nonetheless, ±25% of patients experience severe treatment-related toxicities.
Steendam, Christi M.J., Koch, Birgit C. P., Dingemans, Anne Marie C., Mathijssen, Ron H.J., van der Leest, Cor, Lanser, Daan A.C., Veerman, G. D. Marijn, Agema, Bram C., Steendam, Christi M. J., Preijers, Tim, Dingemans, Anne-Marie C., Dingemans, Anne Marie C.; id_orcid, Preijers, Tim; id_orcid, Lanser, Daan A. C., Koolen, Stijn L.W., Mathijssen, Ron H.J.; id_orcid, Veerman, G. D.Marijn, Koch, Birgit C.P., Mathijssen, Ron H. J., Koolen, Stijn L. W.   +19 more
core   +2 more sources

Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review [PDF]

, 2020
Osimertinib is the standard therapy for epidermal-growth-factor-receptor (EGFR)-mutant lung cancers. We herein report a case of osimertinib-induced interstitial lung disease (OsiILD) with an organizing pneumonia (OP) pattern and provide a literature ...
Hotta, Katsuyuki, Higo, Hisao, Itano, Junko, Nishii, Kazuya, Kiura, Katsuyuki, Makimoto, Go, Maeda, Yoshinobu, Ohashi, Kadoaki, Miyahara, Nobuaki   +8 more
core   +2 more sources

Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization

EBioMedicine, 2022
Summary: Background: The mechanism of missense alteration at EGFR L792F in patients with non-small cell lung cancer resistant to osimertinib has not been sufficiently clarified.
Yiting Sun, Yiting Dong, Xijuan Liu, Yundi Zhang, Hua Bai, Jianchun Duan, Zhihua Tian, Xiang Yan, Jie Wang, Zhijie Wang   +9 more
doaj   +1 more source

Granzyme B PET Imaging Reveals Lgmn+ Macrophage‐Mediated Immune Evasion and Guides Immunotherapy in EGFR‐TKI‐Resistant NSCLC

Advanced Science, EarlyView.
Graphical illustration of 68Ga‐GZB PET/CT imaging reveals immune dynamics post‐EGFR‐TKI resistance in NSCLC; Lgmn+ macrophages‐derived Lgmn‐containing extracellular vesicles inhibit glycolysis, induce CD8+ T cell exhaustion, and targeting Lgmn restores immunotherapy sensitivity.
Dongliang Wang, Wenqin Luo, Qiufang Liu, Wenxuan Tang, Bin Zhu, Jiwei Chen, Qian Zhou, Shuang Tang, Xiaoping Xu, Shaoli Song   +9 more
wiley   +1 more source